Liana Moussatos

Intercept Pharmaceuticals Inc (NASDAQ: ICPT) reported top- and bottom-line beats last week that prompted two Street analysts to upgrade the stock. The Rating Goldman Sachs analyst Salveen Richter upgraded Intercept from Sell to Buy and more than tripled the price target from $46 to $157....

Biotech traders are always on the lookout for stocks with major catalysts on the horizon, and newly-public Kala Pharmaceuticals Inc (NASDAQ: KALA) fits the mold ahead of what will be a critical second half of 2017 for the company. On Monday, Wedbush analyst Liana Moussatos highlighted two key...

Global Blood Therapeutics Inc (NASDAQ: GBT) is in the process of developing GBT440 to reduce the severity and frequency of crises and pain associated with sickle cell disease and to improve blood oxygenation characteristics and quality of life for idiopathic pulmonary fibrosis. The release of Phase...

“While we see potential approval of two products this year and meaningful pipeline progress, we continue to believe BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is relatively expensive as it consistently trades at the top of peers,” Wedbush’s Liana Moussatos said in a note, while...

Miragen Therapeutics, Inc. (NASDAQ: MGEN) appears to be an “attractive investment opportunity,” with its microRNA pipeline demonstrating early clinical efficacy, the presence of near-term catalysts and the potential for “multi-billion dollars in product sales,” Wedbush...

Intercept Pharmaceuticals Inc (NASDAQ: ICPT) hosted a call on Friday to divulge information about changes it made to a late-stage REGENERATE study in Nonalcoholic steatohepatitis, or NASH. Following the call, sell-side analysts gave contrasting views on the development. The Amendments The...

Wedbush’s Liana Moussatos mentioned a slew of potential catalysts that could impact emerging pharmaceutical companies this year. Aimmune Therapeutics Inc (NASDAQ: AIMT) — Rated Outperform, PT: $42 Potential Catalysts First Quarter 2017: Initiate RAMSES trial in the United States. March...

Wedbush has maintained its Outperform rating and $51 price target on Relypsa Inc (NASDAQ: RLYP), saying that the sixth full month of Veltassa's launch figures show growth in all categories, including revenue-generating outpatient prescriptions. Veltassa is a potassium binder approved for the...

In a new report, Wedbush analyst Liana Moussatos breaks down potential 2016 catalysts for every emerging pharmaceuticals stock under the firm’s coverage. Overall, Wedbush is very bullish about these 11 Outperform-rated stocks headed into 2016. Carbylan Therapeutics Inc (NASDAQ: CBYL) Wedbush...

Liana Moussatos of Wedbush overviewed the emerging pharmaceuticals space and offered a scenario analysis of various potential catalysts. Moussatos has the highest degree of confidence on two upcoming catalysts for Relypsa Inc (NASDAQ: RLYP), one of which could see its stock move up or down by as...

Relypsa Inc (NASDAQ: RLYP) shares are up more than 16 percent on Friday afternoon after unconfirmed reports that Merck & Co., Inc. (NYSE: MRK) could make a bid for the $1.07 billion bio therapeutic company. A source familiar with the matter told Benzinga Merck is not involved with a bid, but...